Hyperfine, Inc.
HealthcareNASDAQ:HYPR · NASDAQ Global Market
-$0.06 today
Vol 0.46M · Avg 0.61M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$15.3M of revenue converted into -$34.8M of net income for the selected period. Gross margin is 51.2% and net margin is -248.9%, showing how much revenue survives after costs and taxes. EPS is $-0.41, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.6M +5.2% | $12.9M +16.8% | $11.0M +61.9% | $6.8M +355.5% | $1.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $6.8M -2.7% | $7.0M +11.5% | $6.3M +6.2% | $5.9M +121.8% | $2.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $6.8M +14.6% | $5.9M +23.8% | $4.8M +424.5% | $907.0K +177.7% | -$1.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 49.8% +4.1pp | 45.7% +2.6pp | 43.1% +29.8pp | 13.3% +91.3pp | -78.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $17.5M -22.4% | $22.5M +0.0% | $22.5M -20.1% | $28.2M +9.0% | $25.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $26.4M -0.9% | $26.6M -12.4% | $30.4M -34.8% | $46.6M +23.2% | $37.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $43.8M -10.7% | $49.1M -7.1% | $52.9M -29.3% | $74.8M +17.4% | $63.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.2M +118.1% | $1.0M -4.3% | $1.1M +3.8% | $1.0M +39.8% | $726.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$33.4M +16.0% | -$39.7M +8.0% | -$43.2M +40.1% | -$72.1M -12.5% | -$64.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -246.1% +62.0pp | -308.1% +83.4pp | -391.4% +667.4pp | -1058.8% +3227.6pp | -4286.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$37.1M +14.2% | -$43.2M +10.2% | -$48.1M +34.9% | -$73.9M -13.9% | -$64.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -273.4% +61.9pp | -335.3% +100.8pp | -436.1% +648.0pp | -1084.2% +3251.9pp | -4336.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.0M -58.9% | $2.5M -35.1% | $3.8M +404.9% | $761.0K +4127.8% | $18.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.5M -39.7% | $2.5M -35.4% | $3.9M +446.1% | $710.0K +4076.5% | $17.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$35.6M +12.6% | -$40.7M +8.0% | -$44.2M +39.5% | -$73.2M -12.8% | -$64.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -262.3% +53.6pp | -315.9% +85.1pp | -401.0% +672.7pp | -1073.7% +3261.2pp | -4335.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$35.6M +12.6% | -$40.7M +8.0% | -$44.2M +39.5% | -$73.2M -12.8% | -$64.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -262.3% +53.6pp | -315.9% +85.1pp | -401.0% +672.7pp | -1073.7% +3260.0pp | -4333.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +23.2% | -$1 +9.7% | -$1 +40.4% | -$1 -13.0% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +23.2% | -$1 +9.7% | -$1 +40.4% | -$1 -13.0% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $94.2M +30.1% | $72.4M +1.5% | $71.3M +1.2% | $70.4M +0.2% | $70.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $94.2M +30.1% | $72.4M +1.5% | $71.3M +1.2% | $70.4M +0.2% | $70.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Edap Tms S.a.
EDAP
$178.23M
Quipt Home Medical Corp.
QIPT
$162.30M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
FONAR Corporation
NASDAQ:FONR
$117.76M
AVITA Medical, Inc.
NASDAQ:RCEL
$97.14M
Vivani Medical, Inc.
NASDAQ:VANI
$64.99M
ImageneBio Inc
NASDAQ:IMA
$63.39M
Pulmonx Corporation
NASDAQ:LUNG
$57.86M
InspireMD, Inc.
NSPR
$34.19M
Quince Therapeutics, Inc.
QNCX
$5.20M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does HYPR generate?
Hyperfine, Inc. (HYPR) reported $13.56M of revenue in fiscal 2025.
Is HYPR profitable?
Hyperfine, Inc. (HYPR) reported -$35,574,000.00 of net income, with a net margin of -262.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.